EA202190244A3 - Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков - Google Patents

Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков

Info

Publication number
EA202190244A3
EA202190244A3 EA202190244A EA202190244A EA202190244A3 EA 202190244 A3 EA202190244 A3 EA 202190244A3 EA 202190244 A EA202190244 A EA 202190244A EA 202190244 A EA202190244 A EA 202190244A EA 202190244 A3 EA202190244 A3 EA 202190244A3
Authority
EA
Eurasian Patent Office
Prior art keywords
glycosylation
overexpression
modulation
recombinant proteins
path regulators
Prior art date
Application number
EA202190244A
Other languages
English (en)
Other versions
EA202190244A2 (ru
Inventor
Шивани Гупта
Сохие Канг
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53757626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202190244(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202190244A2 publication Critical patent/EA202190244A2/ru
Publication of EA202190244A3 publication Critical patent/EA202190244A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01101—Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.101)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01094—Protein N-acetylglucosaminyltransferase (2.4.1.94)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01143—Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (2.4.1.143)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Предложены способы модуляции свойств культуры клеток, экспрессирующей необходимый белок. В различных вариантах реализации способы относятся к сверхэкспрессии белков, участвующих в пути N-гликозилирования.
EA202190244A 2014-01-29 2014-12-11 Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков EA202190244A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461933137P 2014-01-29 2014-01-29

Publications (2)

Publication Number Publication Date
EA202190244A2 EA202190244A2 (ru) 2021-05-31
EA202190244A3 true EA202190244A3 (ru) 2021-08-31

Family

ID=53757626

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190244A EA202190244A3 (ru) 2014-01-29 2014-12-11 Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
EA201691532A EA037565B1 (ru) 2014-01-29 2014-12-11 Способ снижения содержания высокоманнозных гликоформ рекомбинантного белка

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201691532A EA037565B1 (ru) 2014-01-29 2014-12-11 Способ снижения содержания высокоманнозных гликоформ рекомбинантного белка

Country Status (14)

Country Link
US (3) US10227627B2 (ru)
EP (1) EP3099806A1 (ru)
JP (4) JP6474420B2 (ru)
KR (3) KR102410393B1 (ru)
CN (2) CN113774084B (ru)
AU (3) AU2014380174B2 (ru)
BR (1) BR112016017606A2 (ru)
CA (1) CA2938079C (ru)
CL (1) CL2016001900A1 (ru)
EA (2) EA202190244A3 (ru)
IL (3) IL282517B (ru)
MX (2) MX2016009911A (ru)
SG (1) SG10201912081RA (ru)
WO (1) WO2015116315A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
MA47775A (fr) * 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
CN109576212B (zh) * 2018-12-14 2021-06-22 杭州奕安济世生物药业有限公司 高密度接种培养中种子细胞的培养方法及其应用
AU2022262421A1 (en) 2021-04-23 2023-10-19 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用
WO2024092064A1 (en) 2022-10-26 2024-05-02 Amgen Inc. Anti-tslp antibody compositions and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
DK1720972T3 (da) * 2004-03-05 2014-04-14 Dsm Ip Assets Bv Fremgangsmåde til celledyrkning ved hjælp af fortløbende perfusion og vekslende tangentialt flow
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US20100221823A1 (en) * 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
TW201028431A (en) * 2008-10-31 2010-08-01 Lonza Ag Novel tools for the production of glycosylated proteins in host cells
WO2010122460A1 (en) * 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20130196410A1 (en) * 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
AU2011237442A1 (en) * 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
TW201209160A (en) 2010-04-27 2012-03-01 Lonza Ag Improved glycosylation of proteins in host cells
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production

Also Published As

Publication number Publication date
KR102410393B1 (ko) 2022-06-16
JP6797950B2 (ja) 2020-12-09
IL282517B (en) 2022-07-01
US10227627B2 (en) 2019-03-12
KR20220086703A (ko) 2022-06-23
IL270861A (en) 2020-01-30
CA2938079C (en) 2022-10-11
JP2019088305A (ja) 2019-06-13
CN106170554A (zh) 2016-11-30
KR102301034B1 (ko) 2021-09-13
EA201691532A1 (ru) 2017-01-30
AU2018264100B2 (en) 2020-07-23
US20190153496A1 (en) 2019-05-23
KR20210114549A (ko) 2021-09-23
JP7034236B2 (ja) 2022-03-11
BR112016017606A2 (pt) 2017-10-10
IL246914A0 (en) 2016-09-29
CN106170554B (zh) 2021-08-17
CN113774084A (zh) 2021-12-10
JP2017505620A (ja) 2017-02-23
SG10201912081RA (en) 2020-02-27
EP3099806A1 (en) 2016-12-07
EA202190244A2 (ru) 2021-05-31
CA2938079A1 (en) 2015-08-06
AU2014380174A1 (en) 2016-08-11
US10907186B2 (en) 2021-02-02
EA037565B1 (ru) 2021-04-14
IL282517A (en) 2021-06-30
IL246914B (en) 2019-12-31
WO2015116315A1 (en) 2015-08-06
CL2016001900A1 (es) 2017-05-12
AU2014380174B2 (en) 2018-08-30
US20200277642A1 (en) 2020-09-03
JP6474420B2 (ja) 2019-02-27
KR20160111943A (ko) 2016-09-27
AU2020239681B2 (en) 2022-06-23
US20190010532A1 (en) 2019-01-10
CN113774084B (zh) 2024-04-16
AU2020239681A1 (en) 2020-10-15
JP2022068365A (ja) 2022-05-09
MX2020012356A (es) 2021-01-29
MX2016009911A (es) 2016-10-28
US10655156B2 (en) 2020-05-19
IL270861B (en) 2021-05-31
JP2021040638A (ja) 2021-03-18
KR102519540B1 (ko) 2023-04-10
AU2018264100A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
EA202190244A2 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
MX2022000302A (es) Moleculas de union que inhiben el crecimiento del cancer.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
UY34885A (es) Proteínas de unión anti-mesotelina
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201791223A1 (ru) Процесс для управления уровнем содержания гликанов гликопротеина
UY34254A (es) Proteínas y péptidos modificados.
EA201491388A1 (ru) Рекомбинантные белки фактора viii
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
CY1120824T1 (el) Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
WO2014140927A3 (en) Proteins with modified glycosylation and methods of production thereof
EA201791918A1 (ru) Модификация белков клеток-хозяев
TW201613631A (en) Ghrelin secretion promoter
IL280553A (en) Cell culture strategies for modulating protein glycosylation
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
EA202191909A1 (ru) Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
MX2016015615A (es) Control de la formacion de enlaces disulfuro en disoluciones de proteinas mediante la adicion de agentes reductores.